RxDoctor Payments Data

Elizabeth Tarsi, MD

Obstetrics & Gynecology · Tupelo, MSNPI 1760917116

Payments from drug & device makers

What this record shows

This record is dominated by grants: $13,601 of the $20,866 with a category attached, or 65.2%. Medtronic accounts for 71.8% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2022 at $10,403 and has fallen 81.7% since, to $1,901 in 2025. Among obstetrics & gynecology clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$20,866in general payments, 2019–2025

Across 89 payments — averaging $234.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$15K
  • Coloplast$3K
  • Axonics, Inc.$3K
  • Boston Scientific$132
  • AbbVie$118
  • Intuitive Surgical$66
  • plus $60 from 1 others

What the payments were for

  • Grants$13,60165%
  • Travel & lodging$4,17820%
  • Food & beverage$2,90414%
  • Education$1831%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,866 in reported general payments places this provider in the 95th percentile of 318 obstetrics & gynecology providers in Mississippi.

See all obstetrics & gynecology providers in Mississippi

Medicare billing

Part B allowed, 2024
$57,436
Medicare patients
113
Services billed
748

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron28$12,861
GemtesaVibegron13$10,132
PremarinEstrogens, Conjugated12$5,182
Estradiol35$2,345
Solifenacin Succinate37$2,250
Methenamine Hippurate14$410
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst22$290
Fluconazole17$99
Gabapentin24$88
Cephalexin16$41
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen15$38
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim17$35

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$60$10,13213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 318 obstetrics & gynecology providers in Mississippi.

Other obstetrics & gynecology in Tupelo

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →